Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2963 - Prognostic significance of BRAF mutation-associated gene signature in colorectal cancer.

Date

09 Sep 2017

Session

Poster display session

Topics

Translational Research;  Colon and Rectal Cancer

Presenters

Jun Eul Hwang

Citation

Annals of Oncology (2017) 28 (suppl_5): v158-v208. 10.1093/annonc/mdx393

Authors

J.E. Hwang1, W.K. Bae1, H. Shim1, S.H. Cho1, I.J. Chung1, K. Kim1, E.C. Hwang2

Author affiliations

  • 1 Medical Oncology, Chonnam National University Medical School & Chonnam National University Hwasun Hospital, 519-809 - Hwasun/KR
  • 2 Urology, Chonnam National University Medical School & Chonnam National University Hwasun Hospital, 519-809 - Hwasun/KR
More

Resources

Abstract 2963

Background

BRAF mutation is associated with poor survival in colorectal cancer. We aimed to generate genomic signature associated with BRAF mutation that possibly predict prognosis in colorectal cancer.

Methods

A gene expression signature reflecting BRAF mutation was generated in TCGA cohorts (n = 207). The colorectal cancer patients were stratified into two groups according to this signature: BRAF mutation type colorectal cancer or BRAF wild type colorectal cancer. Prognostic significance of BRAF mutation-associated gene signature was tested in two other cohorts (GSE 17538, GSE 14333).

Results

The BRAF mutation signature was associated with poor prognosis in two independent cohorts (total n = 522). BRAF mutation signature was associated with poor disease-free survival (median: not reached, P = 0.0303) in GSE14333, and associated with poor overall survival (BRAF mutation vs. wild, P = 0.019 median, 37.310 vs. 134.860 months), and disease-free survival in GSE 17538 (BRAF mutation vs. wild, P = 0.027, median 36.9 months vs. not reached). In a multivariate analysis, BRAF mutation signature was independent poor prognostic factor for disease-free survival (hazard ratio 2.1; 95% CI 1.43-2.62: P = 0.001). Gene network analyses suggested epithelial-mesenchymal transition is the possible explanation for poor prognosis of BRAF mutation colorectal cancer.

Conclusions

BRAF mutation signature is highly associated with poor prognosis in colorectal cancer and the molecules associated with epithelial-mesenchymal transition can be potential treatment targets in BRAF mutation colorectal cancer.

Clinical trial identification

Legal entity responsible for the study

Chonnam National University Hwasun Hospital

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.